Skip to main content
Fig. 7 | Journal of Biomedical Science

Fig. 7

From: Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma

Fig. 7

Clinical activity of HDS in MM patients. A The maximum change of M-protein from baseline level after HDS treatment. B Swim‐lane plot showed the treatment response and duration for 9 MM patients after HDS treatment. Arrows indicated patients who were still ongoing at the time of study closure. PD progressive disease, SD stable disease, MR minimal response. C The protein levels of RRM2 in CD138+ MM cells obtained from patients were evaluated, with GAPDH used as a loading control

Back to article page